Citadel Advisors
CURX

Citadel Advisors’s Curanex Pharmaceuticals CURX Stock Holding History

Citadel Advisors’s Portfolio CURX Stock Details CURX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9K Sell
50,559
-53,719
-52% -$20.2K ﹤0.01% 12618
2025
Q4 		$34.5K Buy
104,278
+40,211
+63% +$22.1K ﹤0.01% 12175
2025
Q3 		$46.1K Buy
+64,067
New +$290K ﹤0.01% 12244

Other funds holding CURX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's CURX Position: Q1 2026 in Review

Citadel Advisors reduced its Curanex Pharmaceuticals (CURX) stake by 52% in Q1 2026, selling an estimated $20.2K and leaving 50,559 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #12618.

Citadel Advisors first reported a position in CURX in Q3 2025 and has held it in 3 quarters since. The position peaked at $46.1K in Q3 2025. 8 funds tracked by Wall St. Rank hold CURX as of Q1 2026.

  • Citadel Advisors held 50,559 shares of Curanex Pharmaceuticals worth $25.9K as of Q1 2026.
  • Citadel Advisors sold 53,719 Curanex Pharmaceuticals shares in Q1 2026, an estimated $20.2K.
  • Curanex Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12618 holding.
  • Citadel Advisors first reported a position in Curanex Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Citadel Advisors's Curanex Pharmaceuticals position peaked at $46.1K in Q3 2025.
  • 8 funds tracked by Wall St. Rank held Curanex Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.